Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Preliminary March 31 cash, cash equivalents and marketable securities of approximately $741 million.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary March 31 cash, cash equivalents and marketable securities of approximately $741 million
- $30 million of legacy asset proceeds collected during the quarter
- Approximately $23 million payable to contingent value rights holders during Q2 2026
- Unaudited figures remain subject to closing procedures and may differ materially from reported results
Item 8.01 · Other Events
- ATM Prospectus suspended and terminated effective April 13, 2026
- No common-stock sales under the Sales Agreement until a new prospectus or registration statement is filed
- Near-term equity issuance paused, reducing immediate dilution risk but limiting a potential funding source
- Sales Agreement with TD Securities remains in force, preserving the ability to restart the ATM program later
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.